Top-line Data on NVG-291 in Healthy Volunteers Expected This Year

Top-line Data on NVG-291 in Healthy Volunteers Expected This Year

303677

Top-line Data on NVG-291 in Healthy Volunteers Expected This Year

NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 — its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions — in healthy volunteers is going according to plan, with early top-line data expected later this year. “The second quarter of 2021 was pivotal for NervGen as we started our Phase 1 clinical trial with NVG-291,” Paul Brennan, NervGen’s president and CEO, said in a…

You must be logged in to read/download the full post.